Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm

  1. Citrome, L.
  2. Sánchez del Rio, M.
  3. Dong, Y.
  4. Nichols, R.M.
  5. Tockhorn-Heidenreich, A.
  6. Foster, S.A.
  7. Stauffer, V.L.
Zeitschrift:
Advances in Therapy

ISSN: 1865-8652,  0741-238X

Datum der Publikation: 2021

Ausgabe: 38

Nummer: 8

Seiten: 4442-4460

Art: Artikel

DOI: 10.1007/S12325-021-01848-X GOOGLE SCHOLAR lock_openOpen Access editor
Datenquelle: Scopus